← Leaderboards
Adeel A Butt
University Of Pittsburgh At Pittsburgh
$975,610
Attributed
$975,610
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $189.4K · FY2005–24$200K$150K$100K$50K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$975,610 · 2
By mechanism
K23$628,422 · 1
R21$347,188 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Matthew S Freiberg$20,071,860
- Inmaculada Hernandez$2,420,658
- Hilary A. Tindle$15,133,646
- Ryan K Shields$1,445,715
- Eric T Roberts$2,071,324
Others in their field
Top investigators on “Comorbidity”
- Judith S. Currier · University Of California Los Angeles$289,742,226
- Daniel R Kuritzkes · Brigham And Women'S Hospital$224,688,794
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$219,177,300
- Sharon A Nachman · Johns Hopkins University$212,395,175
- Michael David Hughes · Harvard University D/B/A Harvard School Of Public Health$130,117,932
- Barbara Driver · Westat, Inc.$112,337,014
Research focus
ComorbidityProviderClinical ResearchMental DisordersPatient /Disease RegistryPharmaceutical PreparationsEmergency CareHepatitis C VirusHospitalizationMedicineDatabasesCommunicable DiseasesAlcoholism /Alcohol AbusePersonsHomelessnessEffectivenessCaringEventCharacteristicsCessation Of LifeIncidenceLaboratoriesNatural HistoryRacial /Ethnic Difference
Grant awards (7)
Oral Antivirals against COVID-19 and Clinical Outcomes in High Risk Populations$189,375
R21 · FY2024 · AI · contact PI
Oral Antivirals against COVID-19 and Clinical Outcomes in High Risk Populations$157,813
R21 · FY2023 · AI · contact PI
Treatment Disparities/Outcomes of HCV-HIV Co-Infection$125,982
K23 · FY2007 · DA · contact PI
Treatment Disparities/Outcomes of HCV-HIV Co-Infection$125,982
K23 · FY2006 · DA · contact PI
Treatment Disparities/Outcomes of HCV-HIV Co-Infection$125,982
K23 · FY2005 · DA
Treatment Disparities/Outcomes of HCV-HIV Co-Infection$125,238
K23 · FY2004 · DA
Treatment Disparities/Outcomes of HCV-HIV Co-Infection$125,238
K23 · FY2003 · DA